El interés en corto de Lantheus Holdings da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Lantheus Holdings. Los datos de interés en corto se actualizan cada dos semanas.

Lantheus Holdings (NASDAQ:LNTH) Bolsa, Informe de interés en corto

Lantheus Holdings

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings Inc

LANTHEUS HOLDINGS ORD

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock moved upwards by 77.9% to $7.49 during Wednesday's regular session. The company's market cap stands at $38.9 million. </li>
<li>Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares moved upwards by 29.22% to $7.03. The company's market cap stands at $924.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) stock increased by 23.78% to $7.13. The market value of their outstanding shares is at $443.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares moved upwards by 21.63% to $2.98. The company's market cap stands at $104.0 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock moved upwards by 21.26% to $0.34. The market value of their outstanding shares is at $10.5 million. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock increased by 16.24% to $5.94. The company's market cap stands at $108.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) stock declined by 39.6% to $3.13 during Wednesday's regular session. The company's market cap stands at $335.3 million. As per the press release, Q3 earnings came out today. </li>
<li>PACS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) shares decreased by 39.39% to $17.91. The market value of their outstanding shares is at $2.7 billion. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock declined by 31.98% to $0.09. The market value of their outstanding shares is at $1.5 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares declined by 31.5% to $1.74. The market value of their outstanding shares is at $1.8 million. </li>
<li>Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock decreased by 27.36% to $51.95. The company's market cap stands at $9.5 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) stock decreased by 22.71% to $88.86. The market value of their outstanding shares is at $6.1 billion. As per the news, the Q3 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BJDX

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CTKB

EXAS

LNTH

OPRX

PACS

RAPT

SONN

TMCI

TNGX

ZVSA

12 Health Care Stocks Moving In Wednesday's Intraday Session

WIIM

Lantheus Holdings shares are trading lower. The company reported Q3 financial results and narrowed its FY24 guidance.

Full Year 2024 Financial Guidance&nbsp; Guidance Issued November 6, 2024 Guidance Issued July 31, 2024 FY 2024 Revenue $1.51 billion - $1.52 billion $1.50 billion - $1.52 billion FY 2024 Adjusted Fully Diluted EPS $6.65 - $6.70 $6.60 - $6.70

Earnings

News

Guidance

Lantheus Narrows 2024 Guidance: Now Sees Revenue Of $1.51B-$1.52B (Prior $1.50B-$1.52B) Vs. $1.52B Est., And Adj. EPS Of $6.65-$6.70 (Prior $6.60-$6.70) Vs. $6.66 Est.

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of $1.56 by 8.97 percent. This is a 15.65 percent increase over earnings of $1.47 per share from the same period last year. The company reported quarterly sales of $378.734 million which beat the analyst consensus estimate of $371.681 million by 1.90 percent. This is a 18.37 percent increase over sales of $319.946 million the same period last year.

Earnings Beats

Lantheus Holdings Q3 2024 Adj. EPS $1.70 Beats $1.56 Estimate, Sales $378.734M Beat $371.681M Estimate

Lantheus Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NYSE">LNTH</a>) short percent of float has risen 3.19% since its last report. The company recently reported that it has 4.25 million shares sold short, which is 8.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lantheus Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730748618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lantheus Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lantheus Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lantheus Holdings's peer group average for short interest as a percentage of float is 7.24%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Lantheus Holdings's Recent Short Interest

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he likes CAVA Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>).
On Oct. 29, Citigroup analyst Jon Tower maintained Cava Group with a Neutral and raised the price target <a href="https://www.benzinga.com/quote/CAVA/analyst-ratings">from $115 to $140.</a>
When asked about GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), he said, &#8220;You have to have planes last longer. And that means more GE business.&#8221;
On Oct. 22, GE Aerospace reported third-quarter 2024 adjusted revenue growth of 6% year-over-year to $8.943 billion and GAAP revenue of $9.84 billion. The analyst consensus was $9.022 billion.
Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) is a &#8220;really good&#8221; company,&#8221; Cramer said. &#8220;It's just one of those companies that you just want to own it — I hate to say this — and forget about it, because that's how good it is.&#8221;
On Oct. 22, Stryker reported quarterly earnings of $2.87 per share which beat the analyst consensus estimate of $2.77 per share. The company reported quarterly sales of $5.49 billion which beat the analyst consensus estimate of $5.37 billion.
Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) is &#8220;very good,&#8221; he said. &#8220;It's a great place to be, particularly with all the things that are being done with AI.&#8221;
Lantheus Holdings will host a conference call on Wednesday, Nov. 6, to discuss its financial and operating results for the third quarter.
Essential Utilities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>) is a &#8220;great&#8221; company, the Mad Money host said. &#8220;That is a terrific stock.&#8221;
Essential Utilities will report earnings for the quarter ending Sept. 30, after the closing bell on Nov. 4.
Price Action:
<ul>
<li>GE Aerospace shares fell 1.6% to settle at $171.78 on Thursday.</li>
<li>Stryker shares dipped 2% to close at $356.28 on Thursday.</li>
<li>Lantheus shares gained 0.4% to settle at $109.84 during the session.</li>
<li>Essential Utilities fell 0.4% to settle at $38.60 on Thursday.</li>
<li>Cava shares fell 0.2% to close at $133.56.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

CAVA

WTRG

Jim Cramer Likes Cava Group, Calls This Utilities Stock 'Terrific'

<ul>
<li>Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival</li>
<li>Overall Response Rate was&nbsp;38.1%&nbsp;vs.&nbsp;12.0%&nbsp;for the ARPI switch arm, including&nbsp;9.3%&nbsp;Complete Responses</li>
<li>Patients demonstrated statistically significant improvement in time to reduction of health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy&mdash;Prostate (FACT-P)</li>
<li>Interim Overall Survival Crossover Adjusted Hazard Ratio was &lt;1.00 when Assessed Using Two-Stage and Inverse Probability Censoring Weighting Methods</li>
<li>Overall Survival data continue to mature, an update is expected once data are available for&nbsp;75%&nbsp;of protocol-specified target OS events</li>
</ul>

Reported Sunday, Lantheus Unveils Phase 3 SPLASH Trial Results In PSMA-Positive Metastatic Prostate Cancer At ESMO 2024

Redburn Atlantic analyst Ed Ridley-Day initiates coverage on Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy rating and announces Price Target of $175.

Price Target

Initiation

Analyst Ratings

Redburn Atlantic Initiates Coverage On Lantheus Holdings with Buy Rating, Announces Price Target of $175

Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that Oliver Sartor, MD, Director of Radiopharmaceutical Trials and Professor of Medical Oncology at the&nbsp;Mayo Clinic&nbsp;in&nbsp;Rochester, Minnesota, will deliver an oral presentation, including additional clinical data from PNT2002's initial December 2023 readout, during the European Society of Medical Oncology (ESMO) Annual Meeting in Barcelona on Sunday, September 15, 2024. &nbsp;

Biotech

General

Lantheus To Present Additional Clinical Data From Phase 3 Pivotal SPLASH Trial In PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress In Barcelona On Sunday, September 15, 2024

JMP Securities analyst David Turkaly maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Market Outperform and lowers the price target from $130 to $125.

JMP Securities Maintains Market Outperform on Lantheus Holdings, Lowers Price Target to $125

Truist Securities analyst Richard Newitter maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and lowers the price target from $141 to $135.

Truist Securities Maintains Buy on Lantheus Holdings, Lowers Price Target to $135

Whales with a lot of money to spend have taken a noticeably bullish stance on Lantheus Holdings.
Looking at options history for Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 33% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $277,310 and 3, calls, for a total amount of $502,500.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90.0 to $155.0 for Lantheus Holdings over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Lantheus Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Lantheus Holdings's significant trades, within a strike price range of $90.0 to $155.0, over the past month.
<h3>Lantheus Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722441659_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LNTH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$21.5</td>
<td>$20.5</td>
<td>$20.5</td>
<td>$90.00</td>
<td>$307.5K</td>
<td>1.2K</td>
<td style="text-align: right;">350</td>
</tr>
<tr>
<td>LNTH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$21.4</td>
<td>$19.5</td>
<td>$19.5</td>
<td>$90.00</td>
<td>$156.0K</td>
<td>1.2K</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>LNTH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$20.5</td>
<td>$19.2</td>
<td>$19.2</td>
<td>$120.00</td>
<td>$67.2K</td>
<td>338</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>LNTH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$9.3</td>
<td>$7.4</td>
<td>$8.5</td>
<td>$110.00</td>
<td>$62.0K</td>
<td>960</td>
<td style="text-align: right;">77</td>
</tr>
<tr>
<td>LNTH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$60.5</td>
<td>$57.3</td>
<td>$57.3</td>
<td>$155.00</td>
<td>$57.3K</td>
<td>0</td>
<td style="text-align: right;">10</td>
</tr>
</tbody>
</table>

<h3>About Lantheus Holdings</h3>
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Following our analysis of the options activities associated with Lantheus Holdings, we pivot to a closer look at the company's own performance.
<h3>Where Is Lantheus Holdings Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,250,895, with LNTH's price down by -16.19%, positioned at $92.0.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
<h3>What The Experts Say On Lantheus Holdings</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $137.75.
<ul>
<li>Maintaining their stance, an analyst from Leerink Partners continues to hold a Outperform rating for Lantheus Holdings, targeting a price of $127. </li>
<li>Consistent in their evaluation, an analyst from B. Riley Securities keeps a Buy rating on Lantheus Holdings with a target price of $146. </li>
<li>Maintaining their stance, an analyst from Jones Trading continues to hold a Buy rating for Lantheus Holdings, targeting a price of $137. </li>
<li>An analyst from Truist Securities has decided to maintain their Buy rating on Lantheus Holdings, which currently sits at a price target of $141. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Lantheus Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Lantheus Holdings's Options Frenzy: What You Need to Know

Lantheus shares are trading lower after the company cut its FY24 EPS outlook.

Full Year 2024 Financial Guidance
<table align="center" cellspacing="0" style="width:100%">
<tbody>
<tr>
<td style="text-align:center; vertical-align:bottom; width:33%">&nbsp;</td>
<td style="text-align:center; vertical-align:bottom; width:33%">Guidance Issued July 31, 2024</td>
<td style="text-align:center; vertical-align:bottom; width:33%">Guidance Issued May 2, 2024</td>
</tr>
<tr>
<td style="vertical-align:bottom">FY 2024 Revenue</td>
<td style="text-align:center; vertical-align:bottom">$1.50 billion - $1.52 billion</td>
<td style="text-align:center; vertical-align:bottom">$1.50 billion - $1.52 billion</td>
</tr>
<tr>
<td style="vertical-align:bottom">FY 2024 Adjusted Fully Diluted EPS</td>
<td style="text-align:center; vertical-align:bottom">$6.60 - $6.70</td>
<td style="text-align:center; vertical-align:bottom">$7.00 - $7.20</td>
</tr>
</tbody>
</table>

Lantheus Cuts FY24 Adj. EPS Outlook Form $7.00-$7.20 To $6.60-$6.70 Vs. $7.07 Estimate, Maintains Revenue Outlook Of $1.50B-$1.52B Vs. $1.51B Estimate

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) reported quarterly earnings of $1.80 per share which missed the analyst consensus estimate of $1.83 by 1.64 percent. This is a 16.88 percent increase over earnings of $1.54 per share from the same period last year. The company reported quarterly sales of $394.091 million which beat the analyst consensus estimate of $382.153 million by 3.12 percent. This is a 22.50 percent increase over sales of $321.700 million the same period last year.

Earnings Misses

Lantheus Q2 2024 Adj. EPS $1.80 Misses $1.83 Estimate, Sales $394.091M Beat $382.153M Estimate

B. Riley Securities analyst Justin Walsh maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and raises the price target from $105 to $146.

B. Riley Securities Maintains Buy on Lantheus Holdings, Raises Price Target to $146

Jones Trading analyst Justin Walsh maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and raises the price target from $128 to $137.

Jones Trading Maintains Buy on Lantheus Holdings, Raises Price Target to $137

FTAI Aviation Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NYSE">FTAI</a>) and Applied Industrial Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) were among <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39797464/small-caps-are-having-a-moment-russell-2000-notches-best-5-day-rally-in-over-4-year">small-cap stocks</a> moving higher on Tuesday as the Russell 2000 Index had a fifth straight day of gains.
The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) gained 3.41% on Tuesday, ushering the index to a cumulative gain of over 9% across <a href="https://www.benzinga.com/topic/small-caps" target="_blank" rel="noreferrer noopener">the last five sessions.</a> This remarkable streak represents the Russell 2000's best five-day performance since June 2020.
FTAI Aviation, a provider of aircraft operations and engine maintenance, rose 5.63% to close at $107.42 on Tuesday, while Applied Industrial gained 4.63% to $210.59.
Also Read: <a href="https://www.benzinga.com/news/small-cap/23/12/36316131/russell-2000-rallies-to-16-month-highs-best-performing-small-cap-stocks-popping-over-80-in-decembe">Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December</a>
FTAI Aviation accounts for 0.39% of the iShares Russell 2000 ETF, while Applied Industrial makes up 0.29% share, <a href="https://www.ishares.com/us/products/239710/ishares-russell-2000-etf">according </a>to iShares by BlackRock.
Individual stocks in the ETF that countered Tuesday&#8217;s small-cap advancement include Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), which fell 3.97% to $118.30.
The rapid rise of small caps is attributed to the growing conviction that the Federal Reserve will lower interest rates at its September meeting. The Russell 2000 rally kicked off last week, driven by June inflation data coming in below expectations, sparking traders' speculation about rate cuts.
According to the CME Group's FedWatch Tool, fed futures now indicate a full 100% probability of an interest rate cut in nearly two months, marking the first reduction in borrowing costs since 2020. On Monday, Fed Chair&nbsp;Jerome Powell&nbsp;struck a dovish tone, acknowledging that recent inflation reports bolster confidence in returning to the 2% target, effectively hinting&nbsp;<a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39779256/powell-praises-latest-inflation-progress-hints-at-imminent-rate-cuts-warns-hes-ve" target="_blank" rel="noreferrer noopener">at forthcoming rate cuts.</a>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/03/37956811/russell-2000-vs-s-p-500-turning-tide-for-small-caps-risk-reward-trade-off-is-very-skewed">Russell 2000 Vs. S&amp;P 500: Turning Tide For Small Caps? &#8216;Risk-Reward Trade-Off Is Very Skewed&#8217;</a></li>
</ul>
Don&#8217;t miss the opportunity to dominate in a volatile market at the&nbsp;<a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" target="_blank" rel="noreferrer noopener">Benzinga SmallCAP Conference</a>&nbsp;on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you&#8217;re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!
Image created using artificial intelligence via Midjourney.

Equities

Federal Reserve

ETFs

FTAI

Russell 2000 Marks Fifth Day Of Gains: What's Driving Surge In Small-Cap Stocks?

Lantheus Acquires Meilleur Technologies, Including The NAV-4694 ß Amyloid PET Imaging Agent For Alzheimer's Disease; Financial Terms Not Disclosed

These eleven mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen's battery company PowerCo <a href="https://www.benzinga.com//node/39727990" target="_blank" rel="noreferrer noopener">to industrialize solid-state batteries</a>.</li>
<li>Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) shares rocketed 55.93% following a CMS proposal to improve payment for Specialized <a href="https://www.benzinga.com//node/39717130" target="_blank" rel="noreferrer noopener">Diagnostic Radiopharmaceuticals</a>.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares increased 37.59%. as shares of companies within the broader industrial sector gained following recent CPI data.</li>
<li>Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) shares rose 37.38% after the company announced its intention to expand Phase 2 trials for Hidradenitis Suppurativa and Atopic Dermatitis to more rapidly progress towards pivotal studies following<a href="https://www.benzinga.com//node/39675035" target="_blank" rel="noreferrer noopener"> an interim review of safety and efficacy</a>.</li>
<li>Apogee Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) shares upped 35.68%.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) stock was up 29.10% after the company announced it successfully flew a hydrogen-electric air taxi demonstrator 523 miles, with <a href="https://www.benzinga.com//node/39733461" target="_blank" rel="noreferrer noopener">water as the only by-product</a>.</li>
<li>Crinetics Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) shares grew 21.18%  after JP Morgan raised its <a href="https://www.benzinga.com/quote/crnx/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $47 to $54</a>.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) stock grew 19.75% after JP Morgan maintained an Overweight rating on the stock and raised its <a href="https://www.benzinga.com/quote/DYN/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $39 to $43</a>.</li>
<li>Summit Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock gained 17.24% in the last week.</li>
<li>Plug Power Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) stock upped 16.51% as EV-related stocks gained <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39728268/inflation-slows-more-expected-to-3-in-june-heightens-expectations-for-rate-cuts-t" target="_blank" rel="noreferrer noopener">following recent CPI Data</a>. The Department of Energy also announced a $1.7 billion to convert 11 shuttered or at-risk auto facilities to manufacture electric vehicles and their supply chain.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) stock rose 15.56%. Shares of Chinese stocks gained following an increase in China's June exports.</li>
</ol>
Also Read
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39763253/rivian-automotive-baidu-are-among-top-11-large-cap-stocks-that-shined-the-brightest-last-week-ju" target="_blank" rel="noreferrer noopener">Rivian Automotive &amp; Baidu Are Among Top 11 Large Cap Stocks That Shined The Brightest Last Week (July 7-July 13): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39763431/netflix-delta-air-lines-and-hubspot-are-among-top-10-large-stocks-that-performed-worst-this-week" target="_blank" rel="noreferrer noopener">Netflix, Delta Air Lines And HubSpot Are Among Top 10 Large Stocks That Performed Worst This Week (July 7-July 13): Are The Others In Your Portfolio?</a></li>
</ul>
Photo Courtesy of QuantumScape

Mid Cap

APGE

CRNX

JOBY

KYMR

PLUG

SMMT

XPEV

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Lantheus (LNTH – Research Report). The company's shar...

Lantheus (LNTH) Gets a Buy from Truist Financial

In a report released today, Matthew Taylor from Jefferies maintained a Buy rating on Lantheus (LNTH – Research Report), with a price target of $145...

Lantheus (LNTH) Gets a Buy from Jefferies

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday. Anthony Petrone has giv...

Lantheus Buy Rating: Favorable CMS Rule and Growth Potential Boost Confidence

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday. Roanna Ruiz's rating is base...

Lantheus Stock Strengthened by Favorable CMS Ruling and Long-term Growth Prospects

Lantheus Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

Lantheus Non-GAAP EPS of $1.70 beats by $0.14, revenue of $378.73M beats by $7.06M

Analyst Tara Bancroft from TD Cowen maintained a Buy rating on Lantheus (LNTH – Research Report) and decreased the price target to $110.00 from $14...

Lantheus's Strong Q3 Performance and Optimistic Pylarify Outlook Amid Revenue Challenges

JonesTrading analyst Justin Walsh reiterated a Buy rating on Lantheus (LNTH – Research Report) today and set a price target of $123.00. Justin Wals...

Lantheus: Strong Growth Potential Amid Challenges with Buy Rating Endorsement

JonesResearch analyst Justin Walsh lowered the firm's price target on Lantheus (LNTH) to $123 from $137 and keeps a Buy rating on the shares follow...

Lantheus price target lowered to $123 from $137 at JonesResearch

ABUS

ADRNY

ATHM

AUDC

BMWYY

CELH

CLBT

CNDT

EHTH

ENOV

FOLD

HENKY

IONS

MCFT

MKTX

MOGO

NEON

OESX

PERI

PFGC

PRGO

RPRX

SNDR

STWD

TCPC

TEVA

TRMB

URGN

VONOY

VRNOF

Press Releases

Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time

Lantheus Reports Second Quarter 2024 Financial Results

Health Care

Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Management

Lantheus Appoints Julie Eastland as New Board Member

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Small Cap

Opinion

Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time

Lantheus Applauds CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care

Comments

Lantheus Holdings

Interés en corto

Lantheus Holdings (NASDAQ:LNTH) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL